BFM
ATXS

Boothbay Fund Management’s Astria Therapeutics ATXS Stock Holding History

Boothbay Fund Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,453
Closed -$358K – 1517
2024
Q1 		$358K Sell
25,453
-36,490
-59% -$454K 0.01% 1138
2023
Q4 		$476K Hold
61,943
– – 0.01% 1003
2023
Q3 		$462K Sell
61,943
-26,716
-30% -$228K 0.01% 1063
2023
Q2 		$739K Sell
88,659
-51,964
-37% -$600K 0.02% 952
2023
Q1 		$1.87M Buy
140,623
+33,801
+32% +$457K 0.04% 695
2022
Q4 		$1.59M Buy
106,822
+5,203
+5% +$53.7K 0.04% 693
2022
Q3 		$919K Buy
101,619
+25,846
+34% +$173K 0.02% 920
2022
Q2 		$227K Buy
+75,773
New +$340K 0.01% 1647
2021
Q3 		– Sell
-14,000
Closed -$177K – 1895
2021
Q2 		$177K Sell
14,000
-1,899
-12% -$24.7K 0.01% 1565
2021
Q1 		$276K Buy
15,899
+4,388
+38% +$79.3K 0.01% 1229
2020
Q4 		$148K Buy
+11,511
New +$205K 0.01% 1132
2018
Q4 		– Sell
-380
Closed -$18K – 660
2018
Q3 		$18K Buy
+380
New +$17.1K ﹤0.01% 761

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Boothbay Fund Management's ATXS Position: Q2 2024 in Review

Boothbay Fund Management sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 25,453 shares — an estimated $358K sold.

Boothbay Fund Management first reported a position in ATXS in Q3 2018 and held it in 12 quarters. The position peaked at $1.87M in Q1 2023. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • Boothbay Fund Management reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 25,453 Astria Therapeutics shares in Q2 2024, an estimated $358K.
  • Boothbay Fund Management first reported a position in Astria Therapeutics in Q3 2018 and held it in 12 quarters.
  • Boothbay Fund Management's Astria Therapeutics position peaked at $1.87M in Q1 2023.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Boothbay Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.